1
|
Kozina EA, Kolacheva AA, Kudrin VS, Kucheryanu VG, Khaindrava VG, Ugryumov MV. Chronic models of the preclinical and early clinical stages of Parkinson’s disease in mice. NEUROCHEM J+ 2016. [DOI: 10.1134/s1819712416030090] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
2
|
Gruden MA, Davydova TV, Narkevich VB, Fomina VG, Wang C, Kudrin VS, Morozova-Roche LA, Sewell RD. Noradrenergic and serotonergic neurochemistry arising from intranasal inoculation with α-synuclein aggregates which incite parkinsonian-like symptoms. Behav Brain Res 2015; 279:191-201. [DOI: 10.1016/j.bbr.2014.11.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2014] [Revised: 10/28/2014] [Accepted: 11/01/2014] [Indexed: 12/13/2022]
|
3
|
Gruden MA, Davydova TV, Narkevich VB, Fomina VG, Wang C, Kudrin VS, Morozova-Roche LA, Sewell RDE. Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates. Behav Brain Res 2014; 263:158-68. [PMID: 24480422 DOI: 10.1016/j.bbr.2014.01.017] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2013] [Revised: 01/11/2014] [Accepted: 01/17/2014] [Indexed: 12/12/2022]
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder in which both alpha-synuclein (α-syn) and dopamine (DA) have a critical role. Our previous studies instigated a novel PD model based on nasal inoculation with α-syn aggregates which expressed parkinsonian-like behavioral and immunological features. The current study in mice substantiated the robustness of the amyloid nasal vector model by examining behavioral consequences with respect to DA-ergic neurochemical corollaries. In vitro generated α-syn oligomers and fibrils were characterized using atomic force microscopy and the thioflavin T binding assay. These toxic oligomers or fibrils administered alone (0.48 mg/kg) or their 50:50 combination (total dose of 0.48 mg/kg) were given intranasally for 14 days and "open-field" behavior was tested on days 0, 15 and 28 of the protocol. Behavioral deficits at the end of the 14-day dosing regime and on day 28 (i.e., 14 days after treatment completion) induced rigidity, hypokinesia and immobility. This was accompanied by elevated nigral but not striatal DA, DOPAC and HVA concentrations in response to dual administration of α-syn oligomers plus fibrils but not the oligomers by themselves. α-Syn fibrils intensified not only the hypokinesia and immobility 14 days post treatment, but also reduced vertical rearing and enhanced DA levels in the substantia nigra. Only nigral DA turnover (DOPAC/DA but not HVA/DA ratio) was augmented in response to fibril treatment but there were no changes in the striatum. Compilation of these novel behavioral and neurochemical findings substantiate the validity of the α-syn nasal vector model for investigating parkinsonian-like symptoms.
Collapse
Affiliation(s)
- Marina A Gruden
- P.K. Anokhin Institute of Normal Physiology, Russian Academy of Medical Science, Moscow, Russia
| | - Tatiana V Davydova
- Institute of General Pathology and Pathophysiology, Russian Academy of Medical Science, Moscow, Russia
| | - Victor B Narkevich
- Institute of Pharmacology, Russian Academy of Medical Science, Moscow, Russia
| | - Valentina G Fomina
- Institute of General Pathology and Pathophysiology, Russian Academy of Medical Science, Moscow, Russia
| | - Chao Wang
- Department of Medical Biochemistry and Biophysics, Umeå University, Umeå SE-90187, Sweden
| | - Vladimir S Kudrin
- Institute of Pharmacology, Russian Academy of Medical Science, Moscow, Russia
| | | | - Robert D E Sewell
- Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK.
| |
Collapse
|
4
|
Nasal inoculation with α-synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine. Behav Brain Res 2013; 243:205-12. [DOI: 10.1016/j.bbr.2013.01.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2012] [Revised: 01/06/2013] [Accepted: 01/10/2013] [Indexed: 12/26/2022]
|
5
|
Khaindrava VG, Kozina EA, Kudrin VS, Kucheryanu VG, Klodt PD, Narkevich VB, Bocharov EV, Nanaev AK, Kryzhanovsky GN, Raevskii KS, Ugrumov MV. Experimental modeling of preclinical and clinical stages of Parkinson's disease. Bull Exp Biol Med 2012; 150:566-9. [PMID: 22235385 DOI: 10.1007/s10517-011-1191-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Degeneration of dopaminergic (DAergic) neurons of the nigrostriatal system is the key stage in the pathogenesis of Parkinson's disease. The first symptoms of this disease are observed after degeneration of 70-80% neurons, which occurs over 20-30 years. The clinical stage of Parkinson's disease begins after this period. Late diagnostics of Parkinson's disease contributes to low efficiency of therapy for this disorder. Detailed study of the pathogenesis and development of preclinical diagnostic methods for Parkinson's disease are the urgent problems. This work was designed to develop a new experimental model of the preclinical and clinical stages of the disease. Experimental modeling was performed on C57Bl/6 mice using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This agent is converted into the MPP(+)-neurotoxin in brain DAergic neurons. We showed that MPTP in a dose of 4 mg/kg has no effect on the nigrostriatal DAergic system. MPTP in a dose of 8-16 mg/kg produced the toxic effect only on DAergic axons, which simulates the preclinical stage of Parkinson's disease. MPTP in a dose of 20-40 mg/kg had the toxic effect on neuronal axons and bodies, which simulates the clinical stage of Parkinson's disease. The data suggest that progressive degeneration of DAergic neurons is accompanied by activation of compensatory mechanisms for functional deficiency of these cells.
Collapse
Affiliation(s)
- V G Khaindrava
- N. K. Kol'tsov Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Ugrumov MV, Khaindrava VG, Kozina EA, Kucheryanu VG, Bocharov EV, Kryzhanovsky GN, Kudrin VS, Narkevich VB, Klodt PM, Rayevsky KS, Pronina TS. Modeling of presymptomatic and symptomatic stages of parkinsonism in mice. Neuroscience 2011; 181:175-88. [PMID: 21382448 DOI: 10.1016/j.neuroscience.2011.03.007] [Citation(s) in RCA: 86] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2010] [Revised: 02/28/2011] [Accepted: 03/01/2011] [Indexed: 12/11/2022]
Abstract
A degradation of the nigrostriatal dopaminergic (DA-ergic) system is the key component of pathogenesis of Parkinson's disease (PD). Initial clinical symptoms appear 20-30 years after the onset of neurodegeneration, at a 70% DA depletion in the striatum and a 50% loss of nigral DA-ergic neurons. Low efficacy of the therapy might be improved if preclinical diagnostics and preventive therapy are developed. The development of appropriate experimental models should precede clinical trials. This multidisciplinary study first managed to model in mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) all together the following stages of parkinsonism: (a) the early presymptomatic stage manifested by a subthreshold degeneration of axons and DA depletion in the striatum without loss of nigral cell bodies; (b) the advanced presymptomatic stage manifested by a subthreshold degeneration of striatal axons and DA depletion and by a subthreshold loss of nigral cell bodies; (c) the advanced presymptomatic stage characterized by threshold depletion of striatal DA and a loss of DA-ergic axons and nigral cell bodies resulting in motor dysfunction. The degeneration of axons proceeds and prevails that of cell bodies suggesting higher sensitivity to MPTP of the former. Compensatory processes were developed in parallel to neurodegeneration that was manifested by the increase of the DA content in individual nigral cell bodies and DA turnover in the striatum. The developed models might be exploited for: (a) an examination of pathogenetic mechanisms not only in the nigrostriatal system but also in other brain regions and in the periphery; (b) a study of the compensatory mechanisms under DA deficiency; (c) a search of precursors of motor disorders and peripheral biomarkers in presymptomatic parkinsonism; (d) the development of preventive therapy aiming to slow down the neurodegeneration and strengthen compensatory processes. Thus, the models of the early and advanced presymptomaic stages and of the early symptomatic stage of parkinsonism were developed in mice with MPTP.
Collapse
Affiliation(s)
- M V Ugrumov
- Laboratory of Hormonal Regulations, Institute of Developmental Biology RAS, 26 Vavilov Street, Moscow 119334, Russia.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Khaindrava VG, Ershov PV, Antsiperov VE, Obukhov YV, Nanaev AK, Ugryumov MV. Optimization of dopaminergic neuron counting in substantia nigra of parkinsonian mice. ACTA ACUST UNITED AC 2010. [DOI: 10.1134/s1990519x10040127] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
8
|
Ma YP, Ma MM, Cheng SM, Ma HH, Yi XM, Xu GL, Liu XF. Intranasal bFGF-induced progenitor cell proliferation and neuroprotection after transient focal cerebral ischemia. Neurosci Lett 2008; 437:93-7. [DOI: 10.1016/j.neulet.2008.04.003] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2008] [Revised: 03/12/2008] [Accepted: 04/01/2008] [Indexed: 10/22/2022]
|
9
|
Zhigaltsev IV, Kaplun AP, Kucheryanu VG, Kryzhanovsky GN, Kolomeichuk SN, Shvets VI, Yurasov VV. LIPOSOMES CONTAINING DOPAMINE ENTRAPPED IN RESPONSE TO TRANSMEMBRANE AMMONIUM SULFATE GRADIENT AS CARRIER SYSTEM FOR DOPAMINE DELIVERY INTO THE BRAIN OF PARKINSONIAN MICE. J Liposome Res 2001; 11:55-71. [DOI: 10.1081/lpr-100103170] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
10
|
Kucheryanu VG, Kryzhanovskii GN. Effect of glutamate and antagonists of N-methyl-D-aspartate receptors on experimental parkinsonian syndrome in rats. Bull Exp Biol Med 2000; 130:629-32. [PMID: 11140570 DOI: 10.1007/bf02682089] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Intranigral administration of glutamate to rats with parkinsonian syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine augmented the development of parkinsonian symptoms (oligokinesia and muscular rigidity), but did not affect motor activity of intact animals. Memantine administered intraperitoneally in parallel with induction of parkinsonian syndrome weakened the development of oligokinesia and muscular rigidity in a dose-dependent manner starting from 5 mg/kg and abolished toxic effect of glutamate. Ketamine (15 mg/kg) under the same conditions less potently prevented the development of oligokinesia, did not prevent the development of muscular rigidity, and did not antagonize glutamate toxicity. The data attest to an important role of glutamate and activation of N-methyl-D-aspartate receptors in the induction and development of parkinsonian syndrome.
Collapse
Affiliation(s)
- V G Kucheryanu
- Laboratory of General Pathophysiology of Nervous System, Institute of General Pathology and Pathological Physiology, Russian Academy of Medical Sciences, Moscow
| | | |
Collapse
|
11
|
Effects of acidic fibroblast growth factor on the development of experimental parkinsonism and striatal level of dopamine and its metabolites in mice of different ages. Bull Exp Biol Med 1999. [DOI: 10.1007/bf02434936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|